See original article on the Canadian Trade Commissioner Service Website BioMedica Diagnostics Inc. is well established as an exporter, with almost 100 percent of the sales of its blood coagulation testing kits, reagents and other products in more than 70 countries around the world.
here For Immediate Release Halifax, NS -Windsor based, BioMedica Diagnostics (BMD) made the announcement today that it has purchases the specialty coagulation business and product line from Sekisui Diagnostics (SDG). The agreement includes all aspects of the business worldwide, with the exception of Europe, Middle East, and Africa, where SDGmbH, a Sekisui Diagnostics subsidiary, will continue to distribute and support the products in partnership with BMD. In conjunction with this agreement, BMD will also acquire the American Diagnostica trademark. “This is great news, not only for BioMedica Diagnostics but for the entire life sciences sector,” Said Scott Moffitt, Managing Director at BioNova – the association leading the development of the life sciences sector in Nova Scotia. ” This acquisition is proof of our global competitiveness and our capabilities to build high growth life sciences companies right here in Nova Scotia.” The agreement closed as of December 1st, 2016 and from this time forward BMD will be responsible for the operation of the business.
-30-About BioMedica Diagnostics Established in 1999, we are a diagnostics company with a focus on providing customized diagnostic solutions in human and animal health. The acquisition of these assets is a natural fit to further solidify our foundation in thrombosis and haemostasis and expand our reach in specialty coagulation. Contact info BioMedica Diagnostics Nadine Williams 902-798-0982 email@example.com BioNova Jessica Gillis, Communications Officer 902-237-8608 firstname.lastname@example.org ]]>
BIOMEDICA DIAGNOSTICS: BioMedica Diagnostics has acquired the specialty coagulation business and product line from Sekisui Diagnostics
See original story here We are pleased to announce today that BioMedica Diagnostics (BMD) has purchased the specialty coagulation business and product line from Sekisui Diagnostics (SDG). The agreement includes all aspects of the business worldwide. In conjunction with this agreement, BMD will also acquire the American Diagnostica trademark. Both BMD and SDG are committed to a seamless transition where maintaining exceptional product quality and the highest service levels for all customers and partners are our top priorities. The agreement closed as of December 1 st , 2016 and from this time forward BMD will be responsible for the operation of the business. Established in 1999, we are a diagnostics company with a focus on providing customized diagnostic solutions in human and animal health. The acquisition of these assets is a natural fit to further solidify our foundation in thrombosis and haemostasis and expand our reach in specialty coagulation. We look forward to continuing to serve customers with the outstanding level of quality and service that partners have come to expect from BMD and SDG. For more information about BioMedica Diagnostics or to purchase products, please contact Nadine Williams at +1-902- 798-0982 or email@example.com.]]>
Dr. Abdullah Kirumira, Chairman and Technical Director, BioMedica Diagnostics In 1993, Dr. Kirumira was responsible for the invention of the world’s first rapid-acting HIV diagnostic test. In 1999, Dr. Abdullah Kirumira founded BioMedica Diagnostics in Windsor, NS, who’s success has been built on their ability to deliver superior service, quality and results to their partners. Dr. Kirumira’s entrepreneurial spirit and willingness to give back has resulted in impressive levels of support in underdeveloped regions lacking the ability diagnose infectious diseases.
Monday, June 6, 2016, BioMedica Diagnostics is proud to announce that it will receive a non-repayable financial contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support research towards a new approach for monitoring blood clotting profiles. This agreement represents funding of up to $371,787, in addition to technical and business advisory services. Over the next two years, NRC-IRAP will provide support to BioMedica Diagnostics on a specific pipeline program that is focused on developing the next generation of innovative and novel base IVD technologies. The new products to be developed will be offered to BioMedica Diagnostics’ global commercial partners. These technologies are focused on ultimately improving diagnosis and patient outcomes, as well as lowering healthcare costs to Canadians and people around the world. At BioMedica Diagnostics, technical innovation is the lifeblood of our operation. The technical and financial support of NRC-IRAP is highly valuable to continue to allow BioMedica Diagnostics to excel in our field. Successful development and commercialization of this important pipeline initiative allows BioMedica Diagnostics to continue to evolve and grow, creating products with positive health impacts together with jobs in Nova Scotia and in Canada, while lending meaningful contributions to the vital Canadian biotechnology community. The team at BioMedica Diagnostics would like to acknowledge and thank the Government of Canada and NRC-IRAP for the support of this exciting project.]]>
BioMedica Diagnostics, a Canadian research and in-vitro-diagnostic solutions company based in Windsor Nova Scotia, has set out to do one thing: “help people live better lives.” This is the approach BioMedica takes with everything they do – from the development of its diagnostic patient-care technologies and solutions, all the way to its collaborative relationships with employees and partners.
When Brian Jeffers took the wheel in 2014 as BioMedica’s new President and CEO, he purposely aimed to build an environment that would attract and retain the best talent. He envisioned a high-performance company culture that enabled individuals to thrive under the concepts of empowerment and accountability. One such individual who understood and bought into the idea of a high-performance culture, and joined BioMedica in an essential role is Sheri Fitzpatrick-Poulain, Director of Commercial Operations.
Together Jeffers and Fitzpatrick-Poulain are building a leadership team of top talent that just happens to be 50% women. This feat landed BioMedica in the spotlight for its approach to gender diversity at BioTalent Canada’s Connecting & Advancing Women in Biotechnology events. With an increased focus in achieving a 50/50 employee gender-balance across multiple sectors, including the Canadian parliament, one can’t help but ask, what lessons can be learned from BioMedica.
The answer is surprising. BioMedica didn’t set out to hire women. Their focus is on talent. “We aim to go after the best talent out there with no internal or external barriers,” said Jeffers. “We focus on someone’s capability as an individual and as a team player, regardless of gender, age or ethnicity.”
Do as you say
BioMedica’s vision of “helping people live better lives” is reflected in the way the company interacts with its team. Fitzpatrick-Poulain said, “we are driven to make the company more successful and in turn are given real workplace flexibility.” Team members can work from home across the country, a benefit that is appreciated companywide. For example, the option to work from home during inclement weather allows everyone on the team to stay safe and focused on their jobs without worrying about issues like childcare and unsafe road conditions. In turn, BioMedica gains an engaged and productive team focused on achieving the objectives that have been set.
Reject artificial harmony
Employees are empowered to take initiative and lead. BioMedica has created an environment where it is safe to disagree and have spirited debates with the objective of getting things right. Office politics and artificial harmony are rejected; instead the focus is on obtaining different perspectives to reach better outcomes for patients and partners alike.
Groom to grow
BioMedica believes in grooming talent to propel the company forward, such as in the case of Fitzpatrick-Poulain, “whose next step in her career is definitely in a President’s role,” said Jeffers. There is a focus on fostering leadership and team building skills, and everyone is given the opportunity to take on more responsibilities and new challenges within the objectives set out. Accountability is a strong pillar of leadership, and rather than point-and-blame, team members are encouraged to take ownership of their mistakes, and come up with solutions. In addition to traditional skills training, team members are actively mentored in every phase of their careers, with the goal of grooming them to grow into leadership positions.
BioMedica understands that its current and future success as a company relies heavily on attracting top talent and creating an environment where they can grow and be empowered to realize their full potential.
Jeffers has a simple answer to the attention BioMedica is getting, “In building our team, we go after the best talent – period. Gender balance is a byproduct of our approach.”